"Folic Acid Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033)
| Descriptor ID |
D005493
|
| MeSH Number(s) |
D27.505.519.389.350
|
| Concept/Terms |
Folic Acid Antagonists- Folic Acid Antagonists
- Acid Antagonists, Folic
- Antagonists, Folic Acid
- Dihydrofolate Reductase Inhibitors
- Inhibitors, Dihydrofolate Reductase
- Reductase Inhibitors, Dihydrofolate
- Antifolates
|
Below are MeSH descriptors whose meaning is more general than "Folic Acid Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Folic Acid Antagonists".
This graph shows the total number of publications written about "Folic Acid Antagonists" by people in this website by year, and whether "Folic Acid Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Folic Acid Antagonists" by people in Profiles.
-
Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Dig Dis Sci. 2014 Nov; 59(11):2831-5.
-
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol. 2012 Jun; 7(6):1041-8.
-
Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. J Thorac Oncol. 2011 Nov; 6(11):1915-22.
-
Genetic and environmental determinants of plasma total homocysteine levels: impact of population-wide folate fortification. Pharmacogenet Genomics. 2011 Jul; 21(7):426-31.
-
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71.
-
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar; 6(1):31-5.
-
Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res. 2005 Nov 15; 11(22):8089-96.
-
Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2005 Aug; 49(8):3463-7.
-
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003 Apr 15; 21(8):1556-61.
-
Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec; 29(6 Suppl 18):49-53.